Compare Adaptive Biotechnologies Corp (ADPT) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Wolfspeed Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.01 (market cap $3.33B), while Wolfspeed Inc trades at $34.99 (market cap $1.87B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | WOLF | |
|---|---|---|
Market Cap | $3.33B | $1.87B |
Sector | Health | Technology |
52-Week High | $22.37 | $73.68 |
52-Week Low | $10.24 | $1.19 |
Enterprise Value | $3.19B | $2.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Wolfspeed (WOLF) trades at $39.47, down 1.33% today, amid bearish technical signals and negative profitability metrics. The company shows strategic progress with AI data center revenue growth and key partnerships, though it faces significant financial challenges with negative gross margins and net losses. Technical indicators show the stock testing support levels with overall bearish momentum despite some neutral oscillators.
The outlook remains cautious with Wall Street divided (31.58% buy ratings) amid ongoing losses and competitive pressures. Near-term catalysts include the Q2 2026 earnings report and execution on defense/aerospace partnerships, but investors face substantial risk from cash burn and market volatility in the semiconductor sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
